Drug Discovery World

JULY 10, 2023

In turn, 100% of the offspring were derived from the ESC component, and approximately 50% of those contained the modified alleleas expected (Fig. In Chimera 2, the percentage of the humanized allele in the sperm (≥ 50%) is consistent with a near-total contribution from the ESC component (a heterozygous ESC clone).

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

Drug Discovery World

APRIL 4, 2023

The approval is for endometrial cancer that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

Drug Discovery World

OCTOBER 25, 2023

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons.

Genome 52

Genome Genomics Gene Scientist 52

The Pharma Data

JANUARY 17, 2021

Forward-looking Statements This Announcement may contain, and the Company may make verbal statements containing “forward-looking statements” with respect to certain of the Company’s plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results.

Containment 52

Containment Genetics Gene Editing Production 52

Drug Discovery World

JANUARY 9, 2024

However, government initiatives to contain healthcare costs, the sustained high cost of capital and global geopolitical disputes are negatively impacting investor appetites for the sector.

Drugs 69

Drugs Antibody Gene Editing Medicine 69

The Pharma Data

NOVEMBER 3, 2020

LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

DECEMBER 28, 2020

Most recently, these companies include: Fibrocor Therapeutics; Encyte Therapeutics (acquired by Zealand Pharma A/S); and Notch Therapeutics, a biotechnology company focused on gene-edited T cell therapies, which has a strategic partnership with Allogene Therapeutics.

Gene Therapy 52

Gene Therapy Life Science Gene Gene Editing 52

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Manufacturing 52

Manufacturing Production Development Clinical Trials 52

The Pharma Data

JANUARY 10, 2021

EDIT-301 is an experimental, ex vivo gene editing cell medicine in development for the treatment of sickle cell disease. Previously, the Company received Rare Pediatric Disease designation from the FDA for EDIT-301. EDIT-301 is the first experimental medicine in development generated using CRISPR/Cas12a gene editing.

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

XTalks

MAY 4, 2021

The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing. It’s a great tool for controlling gene expression.”. pyogenes dCas9.

DNA 98

DNA Gene Gene Silencing Genome 98

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Horizon Discovery Group – U.K.-based for its cGMP-compliant CHOSOURCE platform.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

MAY 2, 2023

The CRISPR-Cas9 system, awarded the Nobel Prize in Chemistry in 2020 for its applications for gene editing, was initially encountered in the bacterial immune system. Pooled CRISPR screens usually employ lentiviral libraries comprising gRNA-containing plasmids packaged into lentiviral particles.

Genome 52

Genome Genomics Gene DNA 52

XTalks

MAY 4, 2021

The CRISPR gene editing system consists of the Cas9 enzyme, which serves as molecular scissors to cleave double-stranded DNA, and a guide RNA template targeted to a specific genomic sequence, which allows for precise editing. It’s a great tool for controlling gene expression.”. pyogenes dCas9.

DNA 52

DNA Gene Gene Silencing Genome 52

XTalks

FEBRUARY 11, 2021

After several such Nobel Prize snubs for female scientists, 2020 saw the Nobel Prize in Chemistry go to a female scientist duo for the first time for their revolutionary discovery of the CRISPR-Cas9 gene editing system. In each of the experiments, they looked at whether the radioactive signal was found in the cell or outside the cell.

Genetics 119

Genetics DNA Genome Genomics 119

The Pharma Data

NOVEMBER 24, 2020

Forward-looking Statements This Announcement may contain, and the Company may make verbal statements containing “forward-looking statements” with respect to certain of the Company’s plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results.

Genetics 40

Genetics Containment Sales Production 40

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. It works by containing lymphocytes within the lymph nodes , preventing them from entering the central nervous system via the blood-brain barrier and causing an autoimmune reaction that destroys myelin on neurons. Pfizer’s total global revenue from Paxlovid was $18.93

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MARCH 11, 2021

Second, the biorevolution is driving innovation in all of Bayer’s divisions – with major progress in cell biology, gene editing and data science. And third, the company is accelerating its transformation and further increasing efficiency.

Sales 52

Sales Gene Therapy Marketing Gene 52

pharmaphorum

NOVEMBER 2, 2021

Droplet digital PCR (ddPCR) technology provides a sensitive, accurate, and absolute quantification of gene edit confirmation in cell line development, and the gene copy number can be reproducibly determined to assure safety and stability.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. VP-102 is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidim delivered by way of a single-use applicator.

Trials 52

Trials Allergies In-Vitro Antibody 52

Drug Discovery World

NOVEMBER 30, 2023

In addition, the company presented three posters: ‘Integration of next-generation transposon vectors with state-of-art host cell lines’, ‘Application of gene editing technologies to improve biotherapeutic manufacturing’, and ‘CHOSOURCE ADCC+ cell line for enhanced therapeutic potency’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Pharma Marketing Network

JANUARY 20, 2021

Assuming these findings are replicated in clinical trials, this vaccine, with its more-appealing route of administration and convenient (refrigerator) storage requirements could make an important contribution to containing the disease.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52